Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 3
2011 2
2012 5
2013 8
2014 5
2015 6
2016 3
2017 2
2018 3
2019 7
2020 6
2021 4
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Drug Choices and Advancements for Managing Depression in Parkinson's Disease.
Assogna F, Pellicano C, Savini C, Macchiusi L, Pellicano GR, Alborghetti M, Caltagirone C, Spalletta G, Pontieri FE. Assogna F, et al. Curr Neuropharmacol. 2020;18(4):277-287. doi: 10.2174/1570159X17666191016094857. Curr Neuropharmacol. 2020. PMID: 31622207 Free PMC article. Review.
Depression is a frequent non-motor symptom of Parkinson's disease (PD), and may even precede the onset of motor symptoms of parkinsonism. ...In general, all traditional antidepressants and some dopamine agonists have been found to be safe and well-tole …
Depression is a frequent non-motor symptom of Parkinson's disease (PD), and may even precede the onset of motor symptom …
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing.
Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier JG, Harold D, Fitzpatrick AL, Valladares O, Moutet ML, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi SH, Mateo I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernadez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamujić-Čomić H, Fr… See abstract for full author list ➔ Kunkle BW, et al. Nat Genet. 2019 Mar;51(3):414-430. doi: 10.1038/s41588-019-0358-2. Epub 2019 Feb 28. Nat Genet. 2019. PMID: 30820047 Free PMC article.
Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. ...Fine-mapping of the human leukocyte antigen (HLA) region confirms the neurological and immune-mediated disease haplotype HLA-DR15 as a risk factor for LO …
Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. ...Fine-mapping of the …
Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes.
Le Guen Y, Luo G, Ambati A, Damotte V, Jansen I, Yu E, Nicolas A, de Rojas I, Peixoto Leal T, Miyashita A, Bellenguez C, Lian MM, Parveen K, Morizono T, Park H, Grenier-Boley B, Naito T, Küçükali F, Talyansky SD, Yogeshwar SM, Sempere V, Satake W, Alvarez V, Arosio B, Belloy ME, Benussi L, Boland A, Borroni B, Bullido MJ, Caffarra P, Clarimon J, Daniele A, Darling D, Debette S, Deleuze JF, Dichgans M, Dufouil C, During E, Düzel E, Galimberti D, Garcia-Ribas G, García-Alberca JM, García-González P, Giedraitis V, Goldhardt O, Graff C, Grünblatt E, Hanon O, Hausner L, Heilmann-Heimbach S, Holstege H, Hort J, Jung YJ, Jürgen D, Kern S, Kuulasmaa T, Lee KH, Lin L, Masullo C, Mecocci P, Mehrabian S, de Mendonça A, Boada M, Mir P, Moebus S, Moreno F, Nacmias B, Nicolas G, Niida S, Nordestgaard BG, Papenberg G, Papma J, Parnetti L, Pasquier F, Pastor P, Peters O, Pijnenburg YAL, Piñol-Ripoll G, Popp J, Porcel LM, Puerta R, Pérez-Tur J, Rainero I, Ramakers I, Real LM, Riedel-Heller S, Rodriguez-Rodriguez E, Ross OA, Royo LJ, Rujescu D, Scarmeas N, Scheltens P, Scherbaum N, Schneider A, Seripa D, Skoog I, Solfrizzi V, Spalletta G, Squassina A, van Swieten J, Sánchez-Valle R, Tan EK, Tegos T… See abstract for full author list ➔ Le Guen Y, et al. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2302720120. doi: 10.1073/pnas.2302720120. Epub 2023 Aug 29. Proc Natl Acad Sci U S A. 2023. PMID: 37643212 Free PMC article.
Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson's disease (PD) and Alzheimer's disease (AD) versus controls. ...
Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson's …
Alexithymia in Parkinson's disease: A systematic review of the literature.
Assogna F, Cravello L, Orfei MD, Cellupica N, Caltagirone C, Spalletta G. Assogna F, et al. Parkinsonism Relat Disord. 2016 Jul;28:1-11. doi: 10.1016/j.parkreldis.2016.03.021. Epub 2016 Mar 30. Parkinsonism Relat Disord. 2016. PMID: 27086264 Review.
INTRODUCTION: In this systematic review, we aimed to evaluate the role of alexithymia in Parkinson's disease (PD) and its relationship to neurological, neuropsychiatric, cognitive, and neuroimaging correlates. ...Two studies on neurological features reported …
INTRODUCTION: In this systematic review, we aimed to evaluate the role of alexithymia in Parkinson's disease (PD) and i …
Anhedonia in Parkinson's disease: a systematic review of the literature.
Assogna F, Cravello L, Caltagirone C, Spalletta G. Assogna F, et al. Mov Disord. 2011 Aug 15;26(10):1825-34. doi: 10.1002/mds.23815. Epub 2011 Jun 9. Mov Disord. 2011. PMID: 21661052 Review.
Relevant journals were hand-searched, and the bibliographies of all the important articles were scrutinized to find additional publications. Fifteen studies assessed the topic of anhedonia in Parkinson's disease from 1984 to 2009 and mainly described it as a …
Relevant journals were hand-searched, and the bibliographies of all the important articles were scrutinized to find additional publications. …
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O; BouNDless Study Group. Espay AJ, et al. Lancet Neurol. 2024 May;23(5):465-476. doi: 10.1016/S1474-4422(24)00052-8. Epub 2024 Mar 15. Lancet Neurol. 2024. PMID: 38499015 Clinical Trial.
BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. ...Eligible participants were men and women aged 30 years or older with a diagnosis of Parkinson's …
BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variatio …
Action observation and motor imagery for rehabilitation in Parkinson's disease: A systematic review and an integrative hypothesis.
Caligiore D, Mustile M, Spalletta G, Baldassarre G. Caligiore D, et al. Neurosci Biobehav Rev. 2017 Jan;72:210-222. doi: 10.1016/j.neubiorev.2016.11.005. Epub 2016 Nov 16. Neurosci Biobehav Rev. 2017. PMID: 27865800 Free article. Review.
This article discusses recent evidence supporting the use of action observation therapy and motor imagery practice for rehabilitation of Parkinson's disease. A main question that emerges from the review regards the different effectiveness of these approaches …
This article discusses recent evidence supporting the use of action observation therapy and motor imagery practice for rehabilitation of …
The recognition of facial emotion expressions in Parkinson's disease.
Assogna F, Pontieri FE, Caltagirone C, Spalletta G. Assogna F, et al. Eur Neuropsychopharmacol. 2008 Nov;18(11):835-48. doi: 10.1016/j.euroneuro.2008.07.004. Epub 2008 Aug 15. Eur Neuropsychopharmacol. 2008. PMID: 18707851 Review.
A limited number of studies in Parkinson's Disease (PD) suggest a disturbance of recognition of facial emotion expressions. ...
A limited number of studies in Parkinson's Disease (PD) suggest a disturbance of recognition of facial emotion expressi …
A metabolic biomarker predicts Parkinson's disease at the early stages in patients and animal models.
Mallet D, Dufourd T, Decourt M, Carcenac C, Bossù P, Verlin L, Fernagut PO, Benoit-Marand M, Spalletta G, Barbier EL, Carnicella S, Sgambato V, Fauvelle F, Boulet S. Mallet D, et al. J Clin Invest. 2022 Feb 15;132(4):e146400. doi: 10.1172/JCI146400. J Clin Invest. 2022. PMID: 34914634 Free PMC article.
BackgroundCare management of Parkinson's disease (PD) patients currently remains symptomatic, mainly because diagnosis relying on the expression of the cardinal motor symptoms is made too late. Earlier detection of PD therefore represents a key step for devel …
BackgroundCare management of Parkinson's disease (PD) patients currently remains symptomatic, mainly because diagnosis …
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
Laansma MA, Bright JK, Al-Bachari S, Anderson TJ, Ard T, Assogna F, Baquero KA, Berendse HW, Blair J, Cendes F, Dalrymple-Alford JC, de Bie RMA, Debove I, Dirkx MF, Druzgal J, Emsley HCA, Garraux G, Guimarães RP, Gutman BA, Helmich RC, Klein JC, Mackay CE, McMillan CT, Melzer TR, Parkes LM, Piras F, Pitcher TL, Poston KL, Rango M, Ribeiro LF, Rocha CS, Rummel C, Santos LSR, Schmidt R, Schwingenschuh P, Spalletta G, Squarcina L, van den Heuvel OA, Vriend C, Wang JJ, Weintraub D, Wiest R, Yasuda CL, Jahanshad N, Thompson PM, van der Werf YD; ENIGMA-Parkinson's Study. Laansma MA, et al. Mov Disord. 2021 Nov;36(11):2583-2594. doi: 10.1002/mds.28706. Epub 2021 Jul 20. Mov Disord. 2021. PMID: 34288137 Free PMC article.
BACKGROUND: Brain structure abnormalities throughout the course of Parkinson's disease have yet to be fully elucidated. OBJECTIVE: Using a multicenter approach and harmonized analysis methods, we aimed to shed light on Parkinson's disease …
BACKGROUND: Brain structure abnormalities throughout the course of Parkinson's disease have yet to be fully elucidated. …
53 results